EBMT 2019 | Potential of CAR T-cells entering the mainstream of cancer treatment

Valentín Ortiz-Maldonado

Valentín Ortiz-Maldonado, MD Hospital Clinic of Barcelona, Barcelona, Spain, shares his view on the evolving role of CAR T-cell therapy for blood cancers in the current immune-oncology era. Speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany, Dr Maldonado reports that based on their significant clinical promise in blood cancer patients, CAR T-cell therapies have a high potential to make it into the mainstream in the near future.

Share this video  
Similar topics